| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
25,260,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Galecto is a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Co.'s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. Co.'s primary product candidate, GB0139, is an inhaled inhibitor of galectin-3. Co. is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
1,265,980 |
1,504,628 |
| Total Sell Value |
$0 |
$0 |
$1,826,954 |
$2,298,562 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
4 |
12 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-08-15 |
4 |
S |
$0.75 |
$617,010 |
I/I |
(822,680) |
1,510,375 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-07-31 |
4 |
S |
$3.00 |
$628,200 |
I/I |
(209,400) |
2,105,909 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-07-25 |
4 |
S |
$2.92 |
$114,464 |
I/I |
(39,200) |
2,258,987 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-07-13 |
4 |
S |
$2.40 |
$467,280 |
I/I |
(194,700) |
2,285,687 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-04-17 |
4 |
S |
$1.97 |
$25,785 |
I/I |
(13,089) |
2,417,787 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-04-14 |
4 |
S |
$1.86 |
$77,090 |
I/I |
(41,446) |
2,426,665 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-04-13 |
4 |
S |
$1.82 |
$25,382 |
I/I |
(13,946) |
2,454,775 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-04-12 |
4 |
S |
$1.81 |
$4,277 |
I/I |
(2,363) |
2,464,234 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-04-11 |
4 |
S |
$1.82 |
$25,382 |
I/I |
(13,946) |
2,465,837 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-04-10 |
4 |
S |
$1.79 |
$91,698 |
I/I |
(51,228) |
2,500,582 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-04-06 |
4 |
S |
$2.00 |
$19,330 |
I/I |
(9,665) |
2,510,041 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2023-04-05 |
4 |
S |
$2.18 |
$202,664 |
I/I |
(92,965) |
2,516,599 |
|
- |
|
| Lindmark Bertil |
Chief Medical Officer |
• – – |
2022-03-22 |
4 |
B |
$2.16 |
$31,545 |
D/D |
14,604 |
16,604 |
2.74 |
- |
|
| Schambye Hans T. |
Chief Executive Officer |
• • – |
2022-03-22 |
4 |
B |
$2.15 |
$10,750 |
D/D |
5,000 |
52,428 |
2.81 |
- |
|
| Freve Jonathan |
Chief Financial Officer |
• – – |
2021-12-03 |
4 |
B |
$2.49 |
$9,960 |
D/D |
4,000 |
12,000 |
2.74 |
- |
|
| Winslow Garrett |
General Counsel |
• – – |
2021-12-03 |
4 |
B |
$2.48 |
$4,960 |
D/D |
2,000 |
4,000 |
2.66 |
- |
|
| Schambye Hans T. |
Chief Executive Officer |
• • – |
2021-11-09 |
4 |
B |
$3.50 |
$15,750 |
D/D |
4,500 |
47,428 |
2.81 |
- |
|
| Freve Jonathan |
Chief Financial Officer |
• – – |
2021-11-08 |
4 |
B |
$3.40 |
$10,200 |
D/D |
3,000 |
8,000 |
2.74 |
- |
|
| Freve Jonathan |
Chief Financial Officer |
• – – |
2021-08-18 |
4 |
B |
$3.92 |
$11,760 |
D/D |
3,000 |
5,000 |
2.74 |
- |
|
| Lindmark Bertil |
Chief Medical Officer |
• – – |
2021-06-28 |
4 |
B |
$5.26 |
$10,520 |
D/D |
2,000 |
2,000 |
2.74 |
- |
|
| Schambye Hans T. |
Chief Executive Officer |
• • – |
2021-06-24 |
4 |
B |
$5.11 |
$15,330 |
D/D |
3,000 |
42,928 |
2.81 |
- |
|
| Freve Jonathan |
Chief Financial Officer |
• – – |
2021-06-23 |
4 |
B |
$4.74 |
$9,480 |
D/D |
2,000 |
2,000 |
2.74 |
- |
|
| Winslow Garrett |
General Counsel |
• – – |
2021-06-23 |
4 |
B |
$4.80 |
$9,600 |
D/D |
2,000 |
2,000 |
2.74 |
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2020-11-02 |
4 |
B |
$15.00 |
$10,999,995 |
I/I |
733,333 |
1,031,811 |
2.25 |
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2020-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,069,922 |
191,787 |
|
- |
|
37 Records found
|
|
Page 1 of 2 |
|
|
